BOSTON, MA -- November 14, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today introduced the Attenuated Total Reflectance (ATR) image accessory for its SpotlightTM FT-IR 400 imaging system. The accessory is optimized to provide the highest quality data while maximizing the available image area. This combination of ATR measurement of large areas within the shortest experiment times increases the information generated and allows more samples to be studied.

ATR is a surface measurement technique that extends the range of samples that can be measured on FT-IR imaging systems, enabling laboratories to get meaningful FT-IR spectra from samples where traditional transmission or reflectance measurements were impossible.

“The PerkinElmer ATR accessory offers an outstanding imaging capability to resolve small material sample features – as small as 3.1 microns,” said Jonathan Rennert, vice president and general manager, Analytical Sciences, PerkinElmer Life and Analytical Sciences. “It provides a much improved sample area compared to other commercially available ATR systems while significantly reducing overall experiment times and consequently increasing throughput.” He added that the accessory complements the existing point ATR measurement capability of PerkinElmer’s FT-IR Imaging Systems.

Preferred over Transmission Sampling in Beta Testing
As a major producer of a wide range of consumer products, Unilever requires many different materials be quickly tested, including detergents, food, hair, packaging materials, and many others. In beta testing at Unilever, the ATR accessory’s spatial resolution of 3.1 microns, up to four times higher than can be achieved with conventional transmission or reflectance imaging, was a major advantage. “We found that the PerkinElmer ATR’s higher spatial resolution made it possible to detect smaller impurities and identify smaller laminates than is possible with transmission sampling,” said Patricia Heussen, chemical analyst, Unilever Research and Development Vlaardingen, The Netherlands.

“The spatial resolution in combination with the larger image area offered a much higher level of certainty that we have captured minor components,” Heussen added. “We are currently in the process of applying the PerkinElmer ATR accessory to a broad range of samples for different research projects and product manufacturing troubleshooting. For example, if there is a problem in a production process, we will be able to quickly identify impurities so they can be eliminated to ensure the integrity of the finished product.

“The Spotlight in combination with the new ATR accessory provides a solution to a wide range of challenges. It enhances rapid understanding of product structures which is a prerequisite for effective product development,” she said.

The range of applications for the ATR accessory is diverse. It can tackle difficult imaging challenges ranging from troubleshooting in chemical and pharmaceutical manufacturing labs to research in academic and independent pharmaceutical and biomedical labs to forensics imaging. Its specially optimized and highly efficient germanium crystal, with a 600-micron diameter sample area, enables laboratories to measure large samples (such as multi-layer laminate sample a few hundred microns across) with excellent signal quality in one operation without having to resort to “stitching” several small images.

The ATR FT-IR Imaging Accessory is the newest addition to PerkinElmer's full range of proven and reliable FT-IR microscopy and imaging systems which are engineered to the highest quality specifications, providing high throughput, reproducibility and ultimately, confidence in the quality of every result.

For more information on the ATR Imaging Accessory, visit www.perkinelmer.com/ATR.

Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," “projects,” “forecasts,” "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.